11 results about "Cotransporter" patented technology

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The invention relates to a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application thereof, and provides a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application of the sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor. In particular, provided are long-acting polypeptides that can be used as NTCP inhibitors. The invention also relates to a preparation method and application of the polypeptide, and a pharmaceutical composition containing the polypeptide. The NTCP long-acting inhibitor competitively inhibits the binding between hepatitis virus surface protein and NTCP through binding with NTCP, realizes the hepatitis virus entry inhibition effect, and can be used as a therapeutic or prophylactic drug for blocking hepatitis virus from entering cells, a hepatitis recurrence inhibition drug and a hepatitis functional curing drug; the compound can also be used as a medicine for treating type II diabetes, a medicine for treating obesity and a medicine for treating intestinal autoimmune diseases, biliary cirrhosis and atherosclerosis.

Disclosed herein are methods of treating metabolic disorders, wherein the method administers a combination of a sodium / glucose co-transporter 1 (SGLT1) inhibitor and a glucagon-like peptide agonist 1 (GLP 1), a Gastrosuppressive Peptide-1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-1 receptor agonist.

Disclosed herein are methods of treating diabetic cardiomyopathy (DbCM) using an aldose reductase inhibitor, and methods of inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM using an aldose reductase inhibitor. Also disclosed are aldose reductase inhibitors and compositions thereof for use in treating diabetic cardiomyopathy (DbCM), or inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM. Subjects treated by the methods and uses are not administered a sodium-glucose cotransporter-2 (SGLT2) inhibitor and / or have an HbA1C value greater than 8.5%.

This disclosure relates to the use of compounds and pharmaceutical compositions thereof in the preparation of medicaments for the prevention and / or treatment of myopia. The compounds disclosed herein are medicaments for treating diabetes, selected from at least one of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, insulin sensitizers, or dipeptidyl peptidase-4 inhibitors. This disclosure provides novel compounds for the prevention and / or treatment of myopia, and to further improve efficacy, this disclosure also provides pharmaceutical compositions comprising said compounds.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

This disclosure relates to the field of diseases caused by reduced synaptic inhibition, preferably diseases caused by reduced activity of the potassium (K) / chloride (Cl) cotransporter (KCC2). This disclosure relates to oligonucleotides in RNA editing methods and their use in targeting adenosine in a codon encoding a phosphorylation site in the SLC12A5 mRNA precursor or mRNA encoding KCC2, preferably adenosine in a codon encoding threonine at position 1007 of the KCC2b isoform. Through editing, threonine is replaced by alanine, thereby removing the phosphorylation site and thereby increasing the activity of the KCC2 protein in a process that restores its GABAergic inhibitory tendency. This disclosure further relates to oligonucleotides for use in the treatment of chronic pain and epilepsy.

The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets sodium-myoinositol cotransporter-1 (SMIT1) or H+- myoinositol transporter (HMIT). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising HMIT, SMIT, and / or SMIT1 (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and / or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.

The present application relates to a kind of dsRNA of prawn SGLT1 gene and its application.The target sequence of the dsRNA is derived from the coding sequence corresponding to the transmembrane region outside loop, intracellular loop or extracellular loop of sodium-dependent glucose cotransporter SGLT1 gene coding protein.The dsRNA of prawn SGLT1 gene provides a new molecular means for preventing and controlling acute hepatopancreas necrosis disease.The dsRNA molecule can be synthesized by in vitro transcription or prokaryotic / eukaryotic expression system, and can be further constructed to contain the sequence expression cassette, recombinant vector and recombinant bacteria.The dsRNA molecule of the present application is small in molecular weight, biodegradable, and will not cause environmental pollution or drug residue, with the advantages of safety, environmental protection, high efficiency and scale production, etc., and can be used as a new biological agent or feed additive for preventing and controlling Vibrio parahaemolyticus AHPND infection.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.